<DOC>
	<DOCNO>NCT01384799</DOCNO>
	<brief_summary>This phase I dose escalation study CUDC-101 combination concurrent cisplatin radiation therapy patient locally advanced head neck cancer . CUDC-101 multi-targeted agent design inhibit epidermal growth factor receptor ( EGFR ) , human epidermal growth factor receptor Type 2 ( Her2 ) histone deacetylase ( HDAC ) . The study design establish safety , tolerability maximum tolerate dose ( MTD ) CUDC-101 administer combination concurrent cisplatin radiation 8-week treatment course , consist one week run-in period CUDC-101 administer alone , follow seven week combination treatment CUDC-101 , cisplatin radiation therapy .</brief_summary>
	<brief_title>Phase I Study CUDC-101 With Cisplatin Radiation Subjects With Head &amp; Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Subjects locally advance , pathologically confirm diagnosis squamous cell carcinoma head neck follow site : oral cavity , oropharynx , hypopharynx larynx either : Stage IV p16 positive tumor &gt; 10 packyears smoke history . Stage III/IV p16 negative tumor , regardless smoke history . At least evaluable disease ; one measurable site disease accord RECIST ( Version 1.1 ) criterion ( least 10 mm conventional CT/MRI spiral CT scan ) desirable . Subjects enrol MTD expansion cohort must least 1 tumor lesion suitable repeat biopsy ( pre postCUDC101 infusion ) . Age ≥ 18 year ECOG performance &lt; 2 Life expectancy ≥ 3 month If female , neither pregnant lactating If child bear potential , must use adequate birth control throughout participation treatment phase 60 day follow last study treatment . Absolute neutrophil count ≥ 1,800/µL ; platelet ≥ 100,000/µL ; hemoglobin ≥ 8.0 g/dL , creatinine ≤ 1.5x upper limit normal ( ULN ) ; total bilirubin ≤ 1.5x ULN ; AST/ALT ≤ 2 x ULN . Serum magnesium potassium within normal limit ( may supplement achieve normal value ) Able render inform consent follow protocol requirement . Prior radiotherapy region study cancer adjacent anatomical site , &gt; 25 % marrowbearing area . Prior chemotherapy current indication . Prior therapy specifically directly target EGFR , HER2 HDAC . Use investigational agent ( ) within 30 day prior study treatment . Primary tumor site nasopharynx , sinus , salivary gland . History cardiac disease New York Heart Association ( NYHA ) Class II great congestive heart failure ( CHF ) , myocardial infarction ( MI ) unstable angina past 6 month prior Day 1 treatment , serious arrhythmia require medication treatment . Patients prolong QTc Interval &gt; 450 msec . Acquired Immune Deficiency Syndrome ( AIDS ) know infection human immunodeficiency virus ( HIV ) . Testing require . Known history gastrointestinal bleeding , ulceration , perforation within 6 month prior study treatment . Known history stroke cerebrovascular accident within 6 month prior study treatment . Symptomatic cardiac conduction abnormality within 12 month prior study treatment . Prior history hearing impairment . Known history renal disease ongoing renal impairment . Any uncontrolled condition ( active systemic infection , diabetes , hypertension ) , opinion investigator , could affect subject participation study . Prior allergic reaction cisplatin , carboplatin platinumcontaining compound . Central nervous system metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>